Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal of Ovarian Research

Fig. 3

From: Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer

Fig. 3

TQ and cisplatin combine to decrease tumor cell proliferation and increase apoptosis. a The percentage of tumor cells positive for proliferation (Ki67/mib-1) and apoptosis (cleaved caspase-3) markers in tumors harvested from ID8-NGL-injected mice treated with vehicle, TQ (20 mg/kg), cisplatin (2 mg/kg) or the TQ/cisplatin combination for 30 days. At least 200 cells were counted (×40 objective) for each drug treatment per experiment. b Representative fields of drug-treated tumors. Ki67/mib-1 or cleaved caspase-3 are in green. DAPI-stained nuclei are in blue. c Western Blot analysis of cleaved PARP (CL PARP), Bax and PCNA in ID8-NGL tumors harvested from drug-treated mice. Actin was used as a loading control. d Densitometry analysis of cleaved PARP, Bax and PCNA expression in tumors relative to corresponding actin levels. Values are mean + SD for 3–5 mice per group; *p < 0.01 relative to vehicle; all p values determined by Mann–Whitney test

Back to article page